Gainers
- Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million.
- Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards by 63.18% to $6.87. The company's market cap stands at $242.6 million. As per the news, the Q2 earnings report came out today.
- MDxHealth (NASDAQ:MDXH) shares moved upwards by 33.13% to $0.62. The market value of their outstanding shares is at $24.1 million. The company's, Q2 earnings came out today.
- Dare Bioscience (NASDAQ:DARE) shares increased by 21.89% to $1.67. The company's market cap stands at $21.5 million. As per the press release, Q2 earnings came out today.
- Eton Pharmaceuticals (NASDAQ:ETON) shares moved upwards by 19.24% to $48.65. The company's market cap stands at $1.1 billion. The company's, Q2 earnings came out today.
- HeartFlow (NASDAQ:HTFL) stock increased by 15.47% to $35.81. The market value of their outstanding shares is at $2.5 billion. As per the press release, Q2 earnings came out today.
Losers
- Cibus (NASDAQ:CBUS) stock decreased by 15.8% to $1.6 during Thursday's after-market session. The market value of their outstanding shares is at $144.2 million. As per the news, the Q2 earnings report came out today.
- Sensus Healthcare (NASDAQ:SRTS) shares declined by 15.51% to $2.67. The market value of their outstanding shares is at $51.5 million. As per the press release, Q2 earnings came out today.
- ARS Pharmaceuticals (NASDAQ:SPRY) stock fell 14.27% to $5.23. The market value of their outstanding shares is at $600.7 million. The company's, Q2 earnings came out today.
- BioXcel Therapeutics (NASDAQ:BTAI) shares declined by 12.39% to $0.99. The company's market cap stands at $32.7 million.
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock fell 10.85% to $3.7. The market value of their outstanding shares is at $307.4 million.
- BeyondSpring (NASDAQ:BYSI) shares declined by 10.72% to $0.89. The company's market cap stands at $30.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Login to comment